Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis

Acta Neurologica Scandinavica

Volumn 113, Issue 5, 2006, Pages 283-287

  Etemadifar, M ^a   Janghorbani, M ^a,b   Shaygannejad, V ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

1b interferon; interferon; Avonex; Betaferon; Efficacy; Multiple sclerosis; Rebif

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 33645470729     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00585.x     Document Type: Article

References (23)

1. J acobs LD C ookfair DL R udick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996 39 285 94.
2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998 352 1498 504.
3. C lark W. Therapeutic advances: interferon for multiple sclerosis. J Clin Pharm Ther 1996 21 195 9.
4. L ublin FD W hitaker JN E ideman BH M iller AE A rnason BG B urks JS. Management of patients receiving interferon β-1b for multiple sclerosis: report of a consensus conference. Neurology 1996 46 12 8.
5. The IFN-β Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multi-centre, randomized, double-blind, placebo-controlled trial. Neurology 1993 43 655 61.
6. W roe SJ. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 2005 33 309 18.
7. S aida T T ashiro K I toyama Y S ato T O hashi Y Z hao Z. Interferon Beta-1b Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005 64 621 30.
8. The IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized, controlled trial. Neurology 1995 45 1277 85.
9. TM): implications for modern MS trials and therapeutics. J Neuroimmunol 2000 107 167 73.
10. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998 352 1498 504.
11. R ice GPA E bers GC. Interferons in the treatment of multiple sclerosis. Do they prevent the progression of the disease Arch Neurol 1998 55 1578 80.
12. F rank JA R ichert N B ash C et al. Interferon-beta-1b slows progression of atrophy in RRMS: three-year follow-up in NAb- and NAb+ patients. Neurology 2004 62 719 25.
13. H aas J F irzlaff M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005 12 425 31.
14. M ilanese C L a M antia L P alumbo R the North Italy Multiple Sclerosis Group A post-marketing study on interferon b 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003 74 1689 92.
15. R io J T intore M N os C T ellez N G alan I M ontalban X. Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. J Neurol 2005 252 795 800.
16. T rojano M L iguori M P aolicelli D et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent post marketing study in southern Italy. Mult Scler 2003 9 451 7.
17. P anitch H G oodin DS F rancis G et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002 59 1496 506.
18. D urelli L V erdun E B arbero P et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 359 1453 60.
19. P oser CM P aty DW S cheinberg L et al. New diagnostic criteria for multiple sclerosis: guideline for research protocol. Ann Neurol 1983 13 227 31.
20. K urtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983 33 1444 52.
21. G ardner MJ A ltman DG. Statistics with confidence. London British Medical Association 1989.
22. R ice G I ncorvaia B M unari L et al. Interferon in relapsing-remitting multiple sclerosis. Cochran Database Syst Rev. 2001 4 CD002002
23. S chultz K C halmers I H ayes RJ A ltman DG. Empirical evidence of bias: dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995 273 408 12.